Bloomage BioTechnology Corporation Limited (SHA: 688363)

China flag China · Delayed Price · Currency is CNY
65.51
+1.54 (2.41%)
Nov 11, 2024, 3:00 PM CST
-15.43%
Market Cap 31.21B
Revenue (ttm) 5.73B
Net Income (ttm) 440.18M
Shares Out 478.36M
EPS (ttm) 0.91
PE Ratio 71.63
Forward PE 44.47
Dividend 0.38 (0.57%)
Ex-Dividend Date Aug 8, 2024
Volume 7,217,252
Open 63.33
Previous Close 63.97
Day's Range 62.93 - 65.56
52-Week Range 44.72 - 84.59
Beta 0.84
Analysts n/a
Price Target n/a
Earnings Date Oct 25, 2024

About Bloomage BioTechnology Corporation

Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature name; and cosmetic grade sodium hyaluronate solutions for cosmetic products, including moisturizing, repairing, delay skin aging, and brightening under th... [Read more]

Sector Materials
Founded 2000
Employees 4,655
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688363
Full Company Profile

Financial Performance

In 2023, Bloomage BioTechnology Corporation's revenue was 6.08 billion, a decrease of -4.45% compared to the previous year's 6.36 billion. Earnings were 592.56 million, a decrease of -38.97%.

Financial Statements

News

There is no news available yet.